Shearman & Sterling represented a syndicate of 18 underwriters represented by Morgan Stanley, Barclays, Citigroup, Goldman, Sachs & Co. and J.P. Morgan in connection with Amgen’s benchmark offering of $4.5 billion of investment grade notes, consisting of $850 million of 1.250% senior notes due 2017, $1.4 billion of 2.200% senior notes due 2019, $1.4 billion of 3.625% senior notes due 2024, $600 million of senior floating rate notes due 2017, and $250 million of senior floating rate notes due 2019.

Amgen is a global biotechnology company that discovers, develops, manufactures and delivers innovative human therapeutics based on advances in cellular and molecular biology.

The Team